FOSTER STOCKBROKING

EQUITY RESEARCH

Healthcare

17 November 2026

Lumos Diagnostics Holdings Ltd (LDX.ASX)

WellStreet on way to 200-plus sites

Event:

- **FebriDx market update; 1QFY27 review; Earnings and PT changes.**

Investment Highlights:

- **WellStreet: going to 200 sites with FebriDx.** LDX last week announced that customer WellStreet is increasing its live (using FebriDx) sites to 141 from 44. Total live sites across all customers is now 365, up from the 265 reported two weeks ago. WellStreet also intends to rollout FebriDx to all its 200+ sites. LDX is targeting achieving this by the end of 2026.
- **Vindication of test's benefits.** It has been over 12 months since WellStreet piloted FebriDx. The progressive rollout to initially 44, now 141, and soon to be 200 centres confirms FebriD'x benefits: antibiotic stewardship, profitable for the clinic, ease of fitting in workflow, rapid results, and patient acceptance.
- **1QFY27 highlights increasing FebriDx sales.** The quarterly showed reported Product sales of US$0.6M, of which we assume FebriDx comprised US$0.5M, bettering our estimate of US$0.1M. However, Group revenue of US$2.0M was short of our forecast US$2.6M due to lower than expected Services sales.
- **Working capital lowers cash.** 1QFY27 cash burn was greater than expected, mostly due to greater working capital investment, and to a lesser extent the lower Services revenue and no BARDA payment (due to lower enrolment and bacterial cases in the paediatric FebriDX CLIA-waiver trial). This resulted in cash end September of US$11.8M vs our US$15.7M estimate.
- **Early in lifecycle**. It is still early in FebriDx's lifecycle to clearly see how uptake will be over the next few quarters. Besides number of sites using FebriDx, uptake is also subject to percentage of ARI patients tested by each clinic (we assume 65% on average), and both seasonality and severity of the flu season.
- **Cash trough in 3QFY27.** FebriDx sales are currently being offset against the Phase Scientific US$5M milestone pre-payment received in April. We still expect the pre-payment to be fully worked through by end 3Q FY27e, by which time we expect cash to trough at US$4.2M.

Earnings and Valuation:

- **Earnings changes.** We cut our FY27 and FY28 forecast LDX NPAT to -US$13M and -US$6M (prior -US$4M and US$7M) on lower Services revenue and higher marketing costs. Post FY29e, our earnings are materially unchanged. We still forecast LDX to be cash flow positive during FY28e as FebriDx sales ramp up.
- **Valuation reduces to $0.49 from $0.51.** Our LDX share valuation falls only modestly since most of our DCF value resides long term, hence only marginal impact from lowered earnings in FY27-29e. As cash troughs, we assume LDX will utilise short-term debt to manage working capital. Alternatively, if equity (say $10M) was raised, our valuation would fall to $0.43.

Recommendation:

- **Maintain Buy and reduce our 12-month price-target to $0.49 from $0.51,** based on valuation. Catalysts include increasing live FebriDx sites, rising FebriDx sales, successful FebriDx pediatric trial, increasing Services contract work, further development for Hologic, and progressing own women's health products.

Disclosures

The analyst owns 417,564 LDX shares. Foster Stockbroking, staff, and Cranport own 3.0% of LDX shares, and 3,120,000 options exercise $0.34, expiry 31 December 2027.
Foster Stockbroking acted as Co-Lead Manager to the $20M placement of LDX shares at $0.225 in March 2026, for which it earned fees. Refer details at end of report.


Recommendation	**Buy**
Previous	Buy
Risk	Medium
Price Target	**$0.49**
Previous	$0.51
Share price (A$)	**$0.071**
ASX code	LDX
52 week low-high	$0.055-0.335
Valuation - risked (A$/share)	**$ 0.49**
Methodology	NPV
Capital structure	
Shares (M)	988
Market cap (A$M)	70
Net cash (debt) (A$M)	17
Performance rights (M)	30
Options (M)	91
Diluted EV (A$M)	64
Ave daily volume ('000)	4,751

Earnings US$M y/e Jun	**FY26a**	**FY27e**	**FY28e**	**FY29e**
Sales	13	21	38	66
EBITDA adj	-12	-12	-1	11
NPAT reported	-5	-13	-6	-5
NPAT adj	**-16**	**-14**	**-6**	**5**
EPS adj. $*	**-0.02**	**-0.01**	**-0.01**	**0.00**
PE x	**nm**	**nm**	**nm**	**11.0x**
EV/EBITDA x	nm	nm	nm	2.6x

** Adj =underlying*

Substantial shareholders	
Tenmile Ventures	19.8%
Ryder Capital	16.7%
Board	
Sam Lanyon	Non-Executive Chair
Doug Ward	CEO &MD
Bronwyn Le Grice	Non-Executive Director
Aizaz Syed	Non-Executive Director
Catherine Robson	Non-Executive Director

Share price graph



Analyst: Mark Fichera +612 9993 8162
mark.fichera@fostock.com.au

DISCLAIMER: Foster Stockbroking Pty Ltd does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest which it seeks to manage and disclose. Refer full disclosures at the end of this report.